PCRX

Pacira BioSciences Inc

36.42

Oct 23 • 3:59 PM ET +0.08 (0.22%)

36.42

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD

Peers: HRTX COLL ANIK INDV BVS AMPH AMRX TLPH VRTX BAX

| Held by: IJR IWM AVUV VTI DFSV VB IJT VBR SPSM IWN

Scroll to Statements

Index	RUT
Market Cap	1.45B
Enterprise Value	1.61B
Income	14.64M
Sales	746.16M
Book/sh	16.87
Cash/sh	6.30
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	829
IPO	Feb 03, 2011

P/E	104.96
Forward P/E	10.53
PEG	0.52
P/S	1.95
P/B	2.16
P/C	5.78
P/FCF	8.09
EV/EBITDA	14.30
EV/Sales	2.16
Quick Ratio	3.94
Current Ratio	5.04
Debt/Eq	0.61
LT Debt/Eq	0.60
Option/Short	Yes / Yes

EPS (ttm)	0.35
EPS next Y	3.46
EPS next Q	0.73
EPS this Y	9.28%
EPS next Y	19.44%
EPS next 5Y	20.25%
EPS past 3/5Y	-22.97% -45.77%
Sales past 3/5Y	2.89% 11.07%
EPS Y/Y TTM	112.73%
Sales Y/Y TTM	5.71%
EPS Q/Q	208.35%
Sales Q/Q	6.24%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	12.95% 0.70%

Insider Own	3.75%
Insider Trans	-2.50%
Inst Own	105.75%
Inst Trans	-8.39%
ROA	1.05%
ROE	2.05%
ROIC	1.36%
Gross Margin	71.53%
Oper. Margin	3.70%
Profit Margin	1.96%
SMA20	14.25%
SMA50	31.04%
SMA200	48.57%
Trades

Shs Outstand	39.82M
Shs Float	38.37M
Short Float	21.05%
Short Ratio	6.53
Short Interest	8.08M
52W High	36.67 -0.67%
52W Low	18.80 93.72%
Volatility	0.22% 1.53%
ATR (14)	0.75
RSI (14)	83.79
Beta	0.26
Rel Volume	0.46
Avg Volume	1.24M
Volume	574,364

Perf Week	0.22%
Perf Month	42.49%
Perf Quarter	37.59%
Perf Half Y	48.59%
Perf YTD	40.73%
Perf Year	68.14%
Perf 3Y	30.02%
Perf 5Y	-30.77%
Perf 10Y	8.39%
Recom	3.00
Target Price	34.79
Prev Close	36.34
Price	36.42
Change %	0.22%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-23-26	Initiated	Oppenheimer	Outperform	$32
Sep-09-26	Initiated	Leerink Partners	Market Perform	$28
Aug-17-26	Resumed	Truist	Buy	$30
Dec-09-25	Initiated	Barclays	Equal Weight	$27
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy	$30
Jan-30-25	Upgrade	Truist	Sell → Hold	$8 → $25
Aug-13-24	Downgrade	Truist	Buy → Sell	$30 → $8
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$37 → $14
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral	$42 → $11
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight	$45 → $10
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight	$38 → $25
Mar-07-24	Resumed	JP Morgan	Overweight	$80 → $45
Dec-20-23	Initiated	Raymond James	Outperform	$42
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform	$50
Jan-31-23	Resumed	Wedbush	Outperform	$88 → $60
Oct-21-22	Resumed	Jefferies	Buy	$66
Jan-03-22	Resumed	JP Morgan	Overweight	$75 → $83
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight	$75

Show Previous Ratings

Oct-12-26 08:50PM	Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders? (PR Newswire)
02:32AM	Stocktwits M&A Watch: Viatris-Pacira Deal, Coca-Colas Costa Coffee Sale, Devons Eagle Ford Divestiture In Focus (Stocktwits)
Oct-09-26 09:12PM	Stocktwits Biotech Dealmaker Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights (Stocktwits)
Oct-08-26 02:31PM	Viatris to acquire Pacira BioSciences for $1.65 billion (Quartz) +44.40%
01:48PM	HAE, PCRX Stocks Hit Multi-Year Highs Amid Broader Market Selloff Whats Driving The Momentum Today? (Stocktwits)
01:20PM	Loading…
01:20PM	Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout (Pharmaceutical Technology)
12:01PM	Pacira BioSciences Stock Surges 44% on $1.7 Billion Viatris Acquisition (Barrons.com)
12:00PM	Viatris boosts pain drug portfolio with $1.7B buyout of Pacira (BioPharma Dive)
11:23AM	2 Stocks Drawing Bearish Options Activity Today (Schaeffer's Research)
10:37AM	Viatris Agrees to Acquire Pacira BioSciences for $1.65 Billion in Non-Opioid Pain Therapy Expansion (InvestorsHub)
09:55AM	Stocks to Watch: Samsung, Pepsi, TSMC (The Wall Street Journal)
08:48AM	Viatris to Buy Pacira BioSciences for $1.65 Billion (The Wall Street Journal)
07:45AM	Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies (PR Newswire)
Oct-07-26 08:00AM	Pacira BioSciences and Caregiver Action Network Announce New Survey on Gaps in Preparing Families for Postsurgical Recovery at Home (GlobeNewswire)
Oct-06-26 06:28AM	Pacira partners with Molteni for Exparel commercialisation (Pharmaceutical Technology)
08:00AM	Loading…
Oct-05-26 08:00AM	Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL in the European Union and United Kingdom (GlobeNewswire)
Sep-09-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-06-26 08:00AM	Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases (GlobeNewswire)
Aug-05-26 01:05AM	Pacira BioSciences Inc (PCRX) (Q2 2026) Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) -9.96%
Aug-04-26 04:01PM	Pacira BioSciences Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-28-26 08:00AM	Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America's Workforce (GlobeNewswire)
Jul-27-26 08:00AM	Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process (GlobeNewswire)
Jul-22-26 08:00AM	Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 (GlobeNewswire)
Jul-08-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-26 08:00AM	Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL (GlobeNewswire)
06:53AM	Zimmer Biomet to acquire iovera device from Pacira for $140m (Medical Device Network)
Jun-30-26 07:30AM	Pacira BioSciences Announces Agreement to Divest its iovera Business to Zimmer Biomet (GlobeNewswire)
07:17AM	Zimmer to buy Pacira pain relief device for up to $140M (MedTech Dive)
Jun-09-26 05:53PM	Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting (PR Newswire)
04:20PM	Loading…
Jun-04-26 04:20PM	Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting (PR Newswire)
Jun-01-26 04:50PM	Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees (PR Newswire)
May-28-26 04:20PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Pacira's Director Nominees (GlobeNewswire)
09:18AM	DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION (PR Newswire)
May-27-26 04:20PM	Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees (GlobeNewswire)
08:00AM	Pacira BioSciences Reports Real-World Study Showing EXPAREL Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty (GlobeNewswire)
May-26-26 08:00AM	Pacira BioSciences Sets the Record Straight Regarding DOMA's Misleading Statements About Pacira's Intellectual Property Strategy (GlobeNewswire)
May-21-26 01:53PM	A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC (PR Newswire)
May-20-26 12:28PM	DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences (PR Newswire)
06:30AM	Pacira BioSciences Files Investor Presentation Highlighting Successful Execution of its Long-Term Strategy to Drive Value for All Stockholders (GlobeNewswire)
May-13-26 10:58AM	DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates (PR Newswire)
08:00AM	Pacira BioSciences to Participate in Fireside Chats at Three Upcoming Healthcare Conferences (GlobeNewswire)
May-12-26 04:01PM	Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees (GlobeNewswire)
May-08-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-05-26 04:20PM	Pacira BioSciences Mails Letter to Stockholders (GlobeNewswire)
May-01-26 03:18AM	Pacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst ... (GuruFocus.com)
Apr-30-26 04:01PM	Pacira BioSciences Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-28-26 04:20PM	Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders (GlobeNewswire)
Apr-27-26 08:00AM	Real-World Data on EXPAREL Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty (GlobeNewswire)
Apr-16-26 08:00AM	Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026 (GlobeNewswire)
Apr-13-26 08:00AM	Pacira Presents Real-World Data on EXPAREL Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures (GlobeNewswire)
Apr-08-26 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-30-26 08:00AM	Pacira BioSciences to Present Real-World Data on EXPAREL Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting (GlobeNewswire)
Mar-11-26 05:02PM	Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation (GlobeNewswire)
01:06PM	DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc. (PR Newswire)
Mar-06-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-26 08:00AM	Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference (GlobeNewswire)
Mar-02-26 08:00AM	Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR) (GlobeNewswire)
Feb-27-26 09:49AM	Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
01:12AM	Pacira BioSciences Q4 Earnings Call Highlights (MarketBeat)
12:06AM	Pacira BioSciences Inc (PCRX) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-26-26 07:30PM	Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:30PM	Pacira (PCRX) Lags Q4 Earnings and Revenue Estimates (Zacks)
04:01PM	Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-12-26 04:01PM	Pacira to Report 2025 Financial Results on Thursday February 26, 2026 (GlobeNewswire)
08:00AM	Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices (GlobeNewswire)
Feb-09-26 08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-26 10:00AM	5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates (Zacks)
Jan-28-26 08:00AM	Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors (GlobeNewswire)
Jan-27-26 12:45PM	Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
12:10PM	Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-16-26 08:30AM	Do Options Traders Know Something About Pacira BioSciences Stock We Don't? (Zacks) -7.22%
Jan-14-26 10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
Jan-13-26 08:00AM	Pacira Announces Agreement with LG Chem to Make EXPAREL Available in Select Asian-Pacific Markets (GlobeNewswire) -5.80%
Jan-12-26 10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
Jan-08-26 04:01PM	Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues (GlobeNewswire) -9.57%
Jan-07-26 08:00AM	Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences (GlobeNewswire)
Dec-31-25 10:45AM	DOMA intends to nominate three director candidates at Pacira annual meeting (TipRanks)
Dec-30-25 10:41AM	DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. (PR Newswire)
Dec-18-25 08:00AM	Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care (GlobeNewswire)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-16-25 02:10PM	Pacira BioSciences Stock Earns Technical Rating Upgrade (Investor's Business Daily)
Dec-03-25 10:23AM	PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain (Zacks)
08:00AM	Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-25 08:00AM	Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera Compared to Radiofrequency Ablation in Chronic Low Back Pain (GlobeNewswire)
Nov-26-25 04:01PM	Pacira BioSciences Files EXPAREL Patent Infringement Lawsuits Against The WhiteOak Group and Qilu Pharmaceutical (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-11-25 08:00AM	Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences (GlobeNewswire)
Nov-10-25 08:09PM	DOMA Perpetual Sends Letter Calling for the Board of Directors of Pacira BioSciences, Inc. to Immediately Explore a Sale of the Business (PR Newswire)
Nov-07-25 12:02AM	Pacira BioSciences Inc (PCRX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Nov-06-25 06:30PM	Pacira (PCRX) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
06:10PM	Pacira (PCRX) Tops Q3 Earnings Estimates (Zacks)
05:06PM	Pacira: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance (GlobeNewswire)
Nov-05-25 08:00AM	Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee (GlobeNewswire)
Nov-04-25 07:00AM	Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control (GlobeNewswire)
Oct-30-25 10:00AM	Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIKER LAUREN	Senior Vice President, Finance	Oct 08 '26	Option Exercise	32.35	6,000	194,100	68,284	Oct 09 07:07 PM
RIKER LAUREN	Senior Vice President, Finance	Oct 08 '26	Sale	36.32	6,000	217,920	62,284	Oct 09 07:07 PM
RIKER LAUREN	Officer	Oct 08 '26	Proposed Sale	36.32	6,000	217,920		Oct 08 10:02 AM
SLONIN JONATHAN	Chief Medical Officer	Aug 17 '26	Sale	23.23	3,040	70,619	216,384	Aug 18 05:21 PM
SLONIN JONATHAN	Officer	Aug 17 '26	Proposed Sale	23.23	3,040	70,619		Aug 17 11:54 AM
RIKER LAUREN	Senior Vice President, Finance	Jun 11 '26	Sale	23.50	6,115	143,702	62,284	Jun 12 09:07 PM
Ceesay Abraham	Director	Jun 12 '26	Proposed Sale	23.27	9,039	210,374		Jun 12 12:15 PM
RIKER LAUREN	Officer	Jun 11 '26	Proposed Sale	23.50	6,115	143,702		Jun 11 11:28 AM
WILLIAMS KRISTEN	Chief Administrative Officer	Jun 04 '26	Sale	22.27	10,259	228,468	167,062	Jun 05 05:57 PM
WILLIAMS KRISTEN	Officer	Jun 04 '26	Proposed Sale	22.27	10,259	228,468		Jun 04 09:48 AM
Cross Shawn	Chief Financial Officer	Apr 23 '26	Option Exercise	16.45	12,941	212,879	118,282	Apr 24 08:41 PM
Cross Shawn	Chief Financial Officer	Apr 23 '26	Sale	25.16	12,941	325,596	105,341	Apr 24 08:41 PM
Cross Shawn	Officer	Apr 23 '26	Proposed Sale	25.16	12,941	325,576		Apr 23 04:41 PM
Cross Shawn	Chief Financial Officer	Apr 20 '26	Option Exercise	16.45	7,714	126,895	113,055	Apr 22 08:03 PM
Cross Shawn	Chief Financial Officer	Apr 21 '26	Option Exercise	16.45	2,845	46,800	108,186	Apr 22 08:03 PM
Cross Shawn	Chief Financial Officer	Apr 22 '26	Option Exercise	16.45	1,500	24,675	106,841	Apr 22 08:03 PM
Cross Shawn	Chief Financial Officer	Apr 20 '26	Sale	25.14	7,714	193,930	105,341	Apr 22 08:03 PM
Cross Shawn	Chief Financial Officer	Apr 21 '26	Sale	25.01	2,845	71,153	105,341	Apr 22 08:03 PM
Cross Shawn	Chief Financial Officer	Apr 22 '26	Sale	25.01	1,500	37,515	105,341	Apr 22 08:03 PM
Cross Shawn	Officer	Apr 22 '26	Proposed Sale	25.01	1,500	37,520		Apr 22 04:20 PM
Cross Shawn	Officer	Apr 21 '26	Proposed Sale	25.01	2,845	71,149		Apr 21 04:20 PM
Cross Shawn	Officer	Apr 20 '26	Proposed Sale	25.14	7,714	193,912		Apr 20 04:11 PM
SLONIN JONATHAN	Chief Medical Officer	Mar 17 '26	Sale	22.82	3,261	74,416	223,640	Mar 19 05:43 PM
Froimson Mark	Director	Mar 17 '26	Sale	21.81	500	10,905	20,136	Mar 19 05:43 PM
Froimson Mark	Director	Mar 17 '26	Proposed Sale	21.81	500	10,905		Mar 17 02:55 PM
SLONIN JONATHAN	Officer	Mar 17 '26	Proposed Sale	22.82	3,261	74,416		Mar 17 11:12 AM
RIKER LAUREN	Senior Vice President, Finance	Feb 02 '26	Sale	20.81	4,000	83,240	52,313	Feb 03 06:24 PM
WILLIAMS KRISTEN	Chief Administrative Officer	Feb 02 '26	Sale	20.53	13,137	269,703	131,303	Feb 03 06:24 PM
RIKER LAUREN	Officer	Feb 02 '26	Proposed Sale	21.05	4,000	84,219		Feb 02 04:12 PM
WILLIAMS KRISTEN	Officer	Feb 02 '26	Proposed Sale	20.53	13,137	269,703		Feb 02 10:55 AM
RIKER LAUREN	Senior Vice President, Finance	Jan 05 '26	Sale	24.24	1,416	34,324	59,064	Jan 06 05:30 PM
RIKER LAUREN	Officer	Jan 05 '26	Proposed Sale	24.24	1,416	34,324		Jan 05 11:22 AM
Cross Shawn	Chief Financial Officer	Dec 09 '25	Option Exercise	16.45	15,896	261,489	72,146	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 10 '25	Option Exercise	16.45	9,104	149,761	65,354	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 09 '25	Sale	25.03	15,896	397,877	56,250	Dec 11 09:47 PM
Cross Shawn	Chief Financial Officer	Dec 10 '25	Sale	25.14	9,104	228,875	56,250	Dec 11 09:47 PM
Cross Shawn	Officer	Dec 10 '25	Proposed Sale	25.14	9,104	228,912		Dec 10 04:41 PM
Cross Shawn	Officer	Dec 09 '25	Proposed Sale	25.03	15,896	397,837		Dec 09 04:31 PM
SLONIN JONATHAN	Chief Medical Officer	Nov 17 '25	Sale	24.09	3,960	95,396	178,367	Nov 19 04:32 PM
SLONIN JONATHAN	Officer	Nov 17 '25	Proposed Sale	24.09	3,960	95,396		Nov 17 10:25 AM
Cross Shawn	Chief Financial Officer	Nov 10 '25	Sale	22.09	12,060	266,405	56,250	Nov 13 04:13 PM
Cross Shawn	Officer	Nov 10 '25	Proposed Sale	22.09	12,060	266,405		Nov 10 10:02 AM

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Brisbane, CA.

CEO & DirectorMr. Frank D. Lee

Chief Financial OfficerMr. Shawn M. Cross

J.D.Ms. Kristen Williams Esq.

Chief Medical OfficerDr. Jonathan Slonin M.D.

Chief Commercial OfficerMr. Brendan P. Teehan

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PCRX

Pacira BioSciences Inc

Upgrade your Finviz experience